Vigilant Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vigilant Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$34K	–	566
2021 Q4	$34K	Hold	200	–	–	﹤0.01%	352
2021 Q3	$38K	Hold	200	–	–	﹤0.01%	290
2021 Q2	$34K	Hold	200	–	–	﹤0.01%	300
2021 Q1	$28K	Hold	200	–	–	﹤0.01%	273
2020 Q4	$26K	Hold	200	–	–	﹤0.01%	266
2020 Q3	$29K	Hold	200	–	–	﹤0.01%	254
2020 Q2	$30K	Hold	200	–	–	﹤0.01%	235
2020 Q1	$22K	Hold	200	–	–	﹤0.01%	250
2019 Q4	$23K	Hold	200	–	–	﹤0.01%	377
2019 Q3	$16K	Hold	200	–	–	﹤0.01%	329
2019 Q2	$15K	Hold	200	–	–	﹤0.01%	334
2019 Q1	$19K	Sell	200 -300	-60%	-$25.1K	﹤0.01%	330
2018 Q4	$36K	Hold	500	–	–	0.01%	277
2018 Q3	$44K	Hold	500	–	–	0.01%	282
2018 Q2	$49K	Hold	500	–	–	0.01%	257
2018 Q1	$60K	Hold	500	–	–	0.01%	215
2017 Q4	$64K	Hold	500	–	–	0.01%	205
2017 Q3	$59K	Buy	500 +300	+150%	+$25.6K	0.01%	173
2017 Q2	$16K	Hold	200	–	–	﹤0.01%	225
2017 Q1	$10K	Hold	200	–	–	﹤0.01%	247
2016 Q4	$7K	Buy	200 +100	+100%	+$4.19K	﹤0.01%	258
2016 Q3	$7K	Buy	+100	New	+$7.05K	﹤0.01%	275
2014 Q1	–	Sell	-450	Closed	-$29K	–	268
2013 Q4	$29K	Buy	+450	New	+$26.8K	0.01%	184

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vigilant Capital Management's ALNY Position: Q1 2022 in Review

Vigilant Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 200 shares — an estimated $34K sold.

Vigilant Capital Management first reported a position in ALNY in Q4 2013 and held it in 23 quarters. The position peaked at $64K in Q4 2017. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

Vigilant Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Vigilant Capital Management sold 200 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $34K.
Vigilant Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 23 quarters.
Vigilant Capital Management's Alnylam Pharmaceuticals position peaked at $64K in Q4 2017.
444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Vigilant Capital Management's 13F filing for Q1 2022, filed 7 Apr 2022.